Pardi D, Black J
CNS Drugs. 2006; 20(12):993-1018.
PMID: 17140279
DOI: 10.2165/00023210-200620120-00004.
Giorgi O, Rubio M
Naunyn Schmiedebergs Arch Pharmacol. 1981; 318(1):14-8.
PMID: 7329448
DOI: 10.1007/BF00503306.
Smialowska M, Slusarska E
J Neural Transm. 1981; 50(1):69-78.
PMID: 7205249
DOI: 10.1007/BF01254915.
Zarrindast M
Br J Pharmacol. 1981; 74(1):119-22.
PMID: 7196787
PMC: 2071871.
DOI: 10.1111/j.1476-5381.1981.tb09962.x.
Ladinsky H, Consolo S, Zatta A, Vezzani A
Naunyn Schmiedebergs Arch Pharmacol. 1983; 322(1):42-8.
PMID: 6843688
DOI: 10.1007/BF00649351.
Increased food intake following the manipulation of intracerebral dopamine levels with gamma-hydroxybutyrate.
Redgrave P, Taha E, White L, Dean P
Psychopharmacology (Berl). 1982; 76(3):273-7.
PMID: 6808549
DOI: 10.1007/BF00432560.
1-Hydroxy-3-amino-pyrrolidone-2(HA-966): a new GABA-like compound, with potential use in extrapyramidal diseases.
Bonta I, de Vos C, Grijsen H, Hillen F, Noach E, Sim A
Br J Pharmacol. 1971; 43(3):514-35.
PMID: 5157720
PMC: 1665789.
DOI: 10.1111/j.1476-5381.1971.tb07182.x.
Release of monoamines from the striatum and hypothalamus: effect of -hydroxybutyrate.
Bustos G, Roth R
Br J Pharmacol. 1972; 46(1):101-15.
PMID: 5084815
PMC: 1666124.
DOI: 10.1111/j.1476-5381.1972.tb06853.x.
Effect of -hydroxybutyrate on the release of monoamines from the rat striatum.
Bustos G, Roth R
Br J Pharmacol. 1972; 44(4):817-20.
PMID: 5041458
PMC: 1665998.
DOI: 10.1111/j.1476-5381.1972.tb07322.x.
The effect of sodium -hydroxybutyrate on the metabolism of dopamine in the brain.
Hutchins D, Rayevsky K, SHARMAN D
Br J Pharmacol. 1972; 46(3):409-15.
PMID: 4656604
PMC: 1666526.
DOI: 10.1111/j.1476-5381.1972.tb08138.x.
Modification of the tremorigenic activity of physostigmine.
Ambrani L, VAN WOERT M
Br J Pharmacol. 1972; 46(2):344-7.
PMID: 4651776
PMC: 1666346.
DOI: 10.1111/j.1476-5381.1972.tb06879.x.
Proceedings: The effects of depleting brain amines on the behavioural actions of gamma-hydroxybutyric acid.
BENTON D, Rick J, Taberner P
Br J Pharmacol. 1974; 52(3):437P-438P.
PMID: 4458857
PMC: 1777025.
Increase in brain dopamine after axotomy or treatment with gammahydroxybutyric acid due to elimination of the nerve impulse flow.
Stock G, Magnusson T, ANDEN N
Naunyn Schmiedebergs Arch Pharmacol. 1973; 278(4):347-61.
PMID: 4269968
DOI: 10.1007/BF00501479.
Interaction of atropine-like drugs with dopamine-containing neurones in rat brain.
BOWERS Jr M, Roth R
Br J Pharmacol. 1972; 44(2):301-6.
PMID: 4148918
PMC: 1666006.
DOI: 10.1111/j.1476-5381.1972.tb07267.x.
Inhibition by gamma-hydroxybutyrate of chlorpromazine-induced increase in homovanillic acid.
Roth R
Br J Pharmacol. 1973; 47(2):408-14.
PMID: 4146575
PMC: 1776541.
DOI: 10.1111/j.1476-5381.1973.tb08338.x.
In vivo voltammetric studies on release mechanisms for cocaine with gamma-butyrolactone.
Broderick P
Pharmacol Biochem Behav. 1991; 40(4):969-75.
PMID: 1816583
PMC: 7133153.
DOI: 10.1016/0091-3057(91)90113-g.
An overview of gamma-hydroxybutyrate catabolism: the role of the cytosolic NADP(+)-dependent oxidoreductase EC 1.1.1.19 and of a mitochondrial hydroxyacid-oxoacid transhydrogenase in the initial, rate-limiting step in this pathway.
KAUFMAN E, Nelson T
Neurochem Res. 1991; 16(9):965-74.
PMID: 1784339
DOI: 10.1007/BF00965839.
Suppression of ethanol-induced locomotor stimulation by GABA-like drugs.
Cott J, Carlsson A, Engel J, Lindqvist M
Naunyn Schmiedebergs Arch Pharmacol. 1976; 295(3):203-9.
PMID: 1012342
DOI: 10.1007/BF00505087.
Effect of anesthetic doses of gamma-hydroxybutyrate on the acetylcholine content of rat brain.
Sethy V, Roth R, Walters J, Marini J, VAN WOERT M
Naunyn Schmiedebergs Arch Pharmacol. 1976; 295(1):9-14.
PMID: 1004645
DOI: 10.1007/BF00509765.
Pharmacological evidence for a selective antidopaminergic action of gamma-hydroxybutyric acid.
Menon K, Bieger D, Hornykiewicz O
J Neural Transm. 1976; 39(3):177-86.
PMID: 978199
DOI: 10.1007/BF01256508.
